Business context and reporting period
Entity mismatch: The request identifies ARTIVION, INC., but the supplied 10-Q is for CryoLife, Inc. and subsidiaries, for the quarter ended March 31, 2012. The summary below describes the supplied filing, not an Artivion filing.
CryoLife preserves and distributes human cardiac and vascular tissues and develops and sells medical devices. Its reportable segments are Preservation Services and Medical Devices. The quarter’s results are unaudited and compared with the three months ended March 31, 2011.
Financial performance and position
| Metric | Q1 2012 | Q1 2011 |
|---|---|---|
| Revenue | $32.301 million | $30.196 million |
| Gross margin | $21.292 million; 65.9% of revenue | $18.504 million; 61.3% of revenue |
| Operating income | $1.629 million; 5.0% margin | $2.447 million; 8.1% margin |
| Net income | $0.991 million | $1.666 million |
| Diluted EPS | $0.04 | $0.06 |
| Cash from operations | $1.805 million | $3.866 million |
- Revenue increased 7%. Product revenue rose 14% to $16.454 million, while preservation services revenue was nearly unchanged at $15.659 million.
- BioGlue and BioFoam revenue rose 14% to $13.696 million, including $1.2 million of Japan sales. Cardiogenesis revascularization technology contributed $2.114 million following its 2011 acquisition. These gains were partly offset by the absence of HemoStase sales and lower PerClot revenue.
- Gross margin improved as preservation processing costs declined, but operating income and net income fell as general, administrative, and marketing expense increased 26% to $17.970 million. The filing attributes the increase largely to expanded sales and marketing activity and legal spending.
- Cash and cash equivalents were $21.146 million at quarter-end, down from $21.705 million at December 31, 2011. Cash used in investing was $0.789 million, including $0.700 million of capital expenditures; cash used in financing was $1.567 million, principally share repurchases.
- Working capital was $63.7 million and the current ratio was 4:1. Total liabilities were $26.102 million. No borrowings were outstanding under the GE Capital facility; $19.8 million remained available. A separate $5.0 million is restricted as facility collateral.
Material changes versus the prior period
- Medical-device revenue benefited from the Cardiogenesis acquisition, which was not reflected in Q1 2011, and record BioGlue revenue. Preservation-service revenue was flat overall: cardiac revenue increased 8%, while vascular revenue decreased 6%.
- Gross margin increased by $2.788 million, but operating expenses rose by $3.606 million, driving operating income down 33% and net income down 41%.
- Operating cash flow declined by $2.061 million, principally due to working-capital demands, including increases in deferred preservation costs and inventories.
- Quarter-end cash was substantially below the $37.582 million reported at March 31, 2011; the filing’s comparative balance sheet instead presents December 31, 2011.
Outlook, commentary, risks, and contingencies
- Management expected full-year 2012 preservation-services revenue to be consistent with 2011. It expected general, administrative, and marketing expenses to remain significantly above comparable 2011 periods, largely due to litigation, and research and development spending to increase for the full year.
- Management stated that existing cash and expected operating cash flows should meet operational liquidity needs for at least 12 months. It also anticipated significant cash demands during the rest of 2012, including clinical trials, litigation, business development, and possible share repurchases; additional financing may be needed for significant future business-development activity.
- PerClot had not received U.S. FDA approval. CryoLife refilled an investigational device exemption in March 2012 to seek permission to begin clinical trials. The company’s expectation of FDA approval by 2014 underpins certain minimum-purchase assumptions and remains uncertain.
- CardioFocus litigation: A trial was scheduled for June 18, 2012. Following adverse pretrial rulings on April 19, management recorded a $933,000 reserve. The company estimated potential damages of $933,000 to $5.0 million before interest if infringement is found; CardioFocus asserted $10.0 million. A materially higher award than the reserve could materially adversely affect financial condition, profitability, and cash flows.
- Medafor litigation: CryoLife said the outcome of its ongoing Georgia case could not be predicted, though management did not expect a material adverse effect. Trial was scheduled for April 2013. A separate Minnesota case was dismissed, with Medafor allowed to amend its complaint.
- Other exposures include estimated net unreported tissue-processing and product-loss liabilities of $1.290 million, with the gross liability potentially as high as $3.8 million under actuarial analysis, and uncertain tax positions estimated at $2.0 million whose payment timing could not be reliably estimated.
- Major business risks cited include dependence on BioGlue, competition and hospital budget pressures, BioGlue patent expirations in 2012–2013, foreign-exchange exposure, tissue supply and product-liability risks, regulatory approval uncertainty, and litigation.
Important facts for investors to verify
- Confirm the filing identity: the supplied report is CryoLife’s 2012 Q1 10-Q, not an Artivion filing.
- Track BioGlue growth and domestic-market competition, including the contribution and sustainability of Japan sales.
- Monitor CardioFocus trial developments, the $933,000 reserve, and potential damages and interest.
- Assess PerClot clinical and FDA progress, related research spending, and purchase commitments.
- Reconcile cash generation and working-capital trends with planned repurchases, litigation costs, and the company’s liquidity outlook.
- Review the full-year expense outlook and whether preservation-service margins remain at the unusually favorable Q1 level; management expected those costs to be more comparable to prior-year periods thereafter.